- Home
- ABUS vs MAX Comparison
ABUS vs MAX Comparison
Compare ABUS & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- MAX
- Stock Information
- Founded
- ABUS 2005
- MAX 2014
- Country
- ABUS United States
- MAX United States
- Employees
- ABUS N/A
- MAX N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- MAX Industrial Machinery/Components
- Sector
- ABUS Health Care
- MAX Industrials
- Exchange
- ABUS Nasdaq
- MAX Nasdaq
- Market Cap
- ABUS 672.1M
- MAX 560.1M
- IPO Year
- ABUS N/A
- MAX 2020
- Fundamental
- Price
- ABUS $3.08
- MAX $10.42
- Analyst Decision
- ABUS Strong Buy
- MAX Buy
- Analyst Count
- ABUS 4
- MAX 8
- Target Price
- ABUS $5.50
- MAX $18.19
- AVG Volume (30 Days)
- ABUS 827.5K
- MAX 593.7K
- Earning Date
- ABUS 05-14-2025
- MAX 04-30-2025
- Dividend Yield
- ABUS N/A
- MAX N/A
- EPS Growth
- ABUS N/A
- MAX N/A
- EPS
- ABUS N/A
- MAX 0.28
- Revenue
- ABUS $6,403,000.00
- MAX $1,002,364,000.00
- Revenue This Year
- ABUS $14.57
- MAX $23.97
- Revenue Next Year
- ABUS $15.84
- MAX $9.79
- P/E Ratio
- ABUS N/A
- MAX $37.42
- Revenue Growth
- ABUS N/A
- MAX 148.62
- 52 Week Low
- ABUS $2.63
- MAX $7.33
- 52 Week High
- ABUS $4.72
- MAX $22.41
- Technical
- Relative Strength Index (RSI)
- ABUS 39.99
- MAX 67.06
- Support Level
- ABUS $2.94
- MAX $10.20
- Resistance Level
- ABUS $3.42
- MAX $10.75
- Average True Range (ATR)
- ABUS 0.18
- MAX 0.47
- MACD
- ABUS -0.04
- MAX 0.14
- Stochastic Oscillator
- ABUS 17.72
- MAX 85.26
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.